Skip to main content

Advertisement

SpringerLink
Log in

Utilization and Antiviral Therapy in Patients with Chronic Hepatitis C: Analysis of Ambulatory Care Visits in the US

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Studies on mostly veterans found the majority of chronic hepatitis C (CHC) patients were not treated. Little information exists on a broad-based population.

Aims

To determine the national trend of ambulatory visits with a diagnosis of hepatitis C and the prescription of antiviral therapy associated with such visits.

Methods

Retrospective analysis of national cross-sectional databases, the National Ambulatory Medical Care Survey (NAMCS), and the National Hospital Ambulatory Medical Care Survey (NHAMCS) encompassing all ambulatory visits from 2000 to 2006.

Results

During the study period, 16.5 million visits (0.21% of all visits) carried a diagnosis of hepatitis C and the number initially increased. Characteristics of the hepatitis C patients were: 65% male; 71% white, 22% black; 69% ≥45 years old. Overall, 47% had private insurance, 24% had Medicaid, and 12% had Medicare. Only 9.1% of these patients were prescribed antiviral treatment for CHC. There was no significant difference between those who received treatment and those who did not in terms of age, gender, race, and insurance status. HIV infection, mood, substance-use disorders, and anemia were more common in the CHC group.

Conclusions

Less than 10% of the ambulatory visits for hepatitis C were associated with a prescription for antiviral therapy, independent of demographic and insurance status. Purposes of the clinic visits were different in the CHC group compared to the general population. The reason for the low treatment rate is not clear but deserves further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714.

    PubMed  Google Scholar 

  2. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385–389.

    Article  PubMed  Google Scholar 

  3. Shatin D, Schech SD, Patel K, McHutchison JG. Population-based hepatitis C surveillance and treatment in a national managed care organization. Am J Manag Care. 2004;10:250–256.

    PubMed  Google Scholar 

  4. Bobbola M, Momi J, Lim JK, Ready J, Cheung RC. Practice patterns and treatment outcomes in the management of chronic hepatitis C (CHC) in a large management care cohort. Abstract presented at the annual meeting of the American College of Gastroenterology; 2005.

  5. Manos M, Shvachko V, Zhao W, Murphy RC. Determinants of HCV antiviral treatment in a managed care setting. Hepatology. 2008;48:866A.

    Google Scholar 

  6. Cherry DK, Hing E, Woodwell DA, Recher EA. National ambulatory medical care survey: 2006 Summary. National Health Statistics Reports, Number 3, August 6; 2008.

  7. Centers for Disease Control and Prevention. National ambulatory care survey (NAMCS) and National hospital ambulatory medical care survey (NHAMCS) lists of publications (updated 1/6/2009). http://www.cdc.gov/nchs/data/ahcd/publist-01-06-09.pdf; 2009 Accessed 8 Jan 2009.

  8. Elixhauser A, Steiner C, Palmer L. Clinical Classifications Software (CCS), 2008. U.S. Agency for Healthcare Research and Quality. http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp; 2009 Accessed 8 Jan 2009.

  9. Cheung RC, Cunningham BA, Cooper AD. Effectiveness of a screening program for hepatitis C. Dig Dis Sci. 2006;51:976–981.

    Article  PubMed  Google Scholar 

  10. Falck-Ytter Y, Kate H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136:288–292.

    CAS  PubMed  Google Scholar 

  11. Araya V, Basi PS, Feyssa E, Malek A, et al. The majority of HCV-infected patients presenting to a large hepatology practice in an urban setting cannot be treated with pegylated interferon and ribavirin due to psychosocial factors in spite of universal health insurance access. Gastroenterology. 2009;136(Suppl 1):S2079.

    Google Scholar 

  12. Muir AJ, Provenzale D. A descriptive evaluation of eligibility for treatment among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol. 2002;34:268–271.

    Article  PubMed  Google Scholar 

  13. Bini EJ, Brau N, Currie S, Shen H, et al. Prospective multicenter study of eligibility for anti-viral therapy among 4,084 U.S. veterans with chronic hepatitis C infection. Am J Gastroeneterol. 2005;100:1772–1779.

    Article  Google Scholar 

  14. Groom H, Dieperink E, Nelson DB, Garrard J, et al. Outcomes of a hepatitis C screening program in a large urban VA medical center. J Clin Gastroenterol. 2008;42:97–106.

    Article  PubMed  Google Scholar 

  15. Hing E, Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2003 Summary. Advance data from vital and health statistics; no 365. 2003 NAMCS micro-data file documentation 2004 NAMCS micro-data file documentation. http://www.cdc.gov/nchs/data/ad/ad365.pdf; 2009 Accessed 8 Jan 2009.

  16. Yates WR, Gleason O. Hepatitis C and depression. Depress Anxiety. 1998;7:188–193.

    Article  CAS  PubMed  Google Scholar 

  17. El-Serag HB, Kunik M, Richardson P, et al. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002;123:476–482.

    Article  PubMed  Google Scholar 

  18. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting the future healthcare burden from hepatitis C in the United States. Liver Transpl. 2003;9:331–338.

    Article  PubMed  Google Scholar 

  19. Myers RP, Liu M, Shaheen AA. The burden of hepatitis C infection is growing: a Canadian population-based study of hospitalization from 1994 to 2004. Can J Gastroenterol. 2008;22:381–387.

    PubMed  Google Scholar 

  20. Bruno S, Stroffolini T, Colombo M, Bollani S, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–587.

    Article  CAS  PubMed  Google Scholar 

  21. Veldt BJ, Heathcote JE, Wedemeyer H, Reichen J, et al. Sustained virological response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–684.

    PubMed  Google Scholar 

  22. John-Baptiste AA, Tomlinson G, Hsu PC, Krajden M et al. Sustained responders have better quality of life and productivity compared with treatment failure long after antiviral therapy for hepatitis C. Am J Gastroenterol. 2009 (epub ahead of print).

  23. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, et al. Clinical, virological, histological, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49:729–738.

    Article  CAS  PubMed  Google Scholar 

  24. Butt AA, Wang X, Moore CG. Effect of hepatitis C and its treatment on survival. Hepatology. 2009;50:387–392.

    Article  PubMed  Google Scholar 

  25. Berenguer J, Alverez-Pellicer J, Martin PM, Lopez-Aldeguer J, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complication and mortality in patients co-infected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50:407–413.

    Article  CAS  PubMed  Google Scholar 

  26. Butt AA, Khan UA, Shaikh OS, McMahon D, et al. Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials. 2009;10:25–32.

    Article  PubMed  Google Scholar 

  27. Butt AA, Tsevat J, Leonard AC, Shaikh OS, et al. Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus. Int J Infect Dis. 2009;13:449–455.

    Article  PubMed  Google Scholar 

  28. Pyenson B, Fitch K, Iwasaki K. Consequences of Hepatitis C Virus (HCV): Cost of a Baby Boomer Epidemic of Liver Disease. Seattle: Milliman, 2009. Commissioned by the Vertex Pharmaceuticals Incorporated.

  29. Zhang H, Mehra M, DiBello J. Increase in CHC Treatment Rate in the US is a Cost-saving Strategy. Presented at the 44th annual meeting of the European Association for the Study of the Liver. Copenhagen, Denmark, April 22–26, 2009.

  30. Zhang H, Mehra M, DiBello J. US Hepatitis C Burden Assessment from a Transmission Model. Presented at the 44th annual meeting of the European Association for the Study of the Liver, Copenhagen, Denmark, April 22–26 2009.

  31. Ruhl CS, Sayer B. Summary of surveys used in the burden of digestive diseases in the United States. In: Everhart JE, ed. The burden of digestive diseases in the United States. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office; 2008: NIH Publication No. 09-6443, pp. 153–155.

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA, USA

    Ramsey Cheung, Ajitha Mannalithara & Gurkirpal Singh

  2. Division of Gastroenterology and Hepatology, VA Palo Alto Health Care System (154C), 3801 Miranda Ave, Palo Alto, CA, 94304, USA

    Ramsey Cheung

  3. Institute of Clinical Outcomes Research and Education, Palo Alto, CA, USA

    Gurkirpal Singh

Authors
  1. Ramsey Cheung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ajitha Mannalithara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gurkirpal Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ramsey Cheung.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cheung, R., Mannalithara, A. & Singh, G. Utilization and Antiviral Therapy in Patients with Chronic Hepatitis C: Analysis of Ambulatory Care Visits in the US. Dig Dis Sci 55, 1744–1751 (2010). https://doi.org/10.1007/s10620-010-1147-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-010-1147-z

Keywords

Search

Navigation